Biogen’s successful quarter was bolstered by the success of their product portfolio which includes the company’s blockbuster drug TECFIDERA® which is an oral therapy approved for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Since the launch of TECFIDERA®, the drug has been extremely successful in the US market with additional revenue growth boosted by increased adoption in new markets worldwide. TECFIDERA revenues totaled $700 million, consisting of $585 million in U.S. sales and $115 million in sales outside the U.S. Biogen’s AVONEX®, a treatment used to slow the progression of disability and reduce relapses for relapsing forms of MS garnered $774 million in sales with $498 million in US and $276 million ouside of the US. TYSABRI, another key player brought in $533 million, which consisted of $250 million in U.S. sales and $284 million in sales outside the U.S.
Other main contributors include RITUXAN® and GAZYVA® with an earnings portfolio of $303 million in the second quarter of 2014, compared to $289 million in the second quarter of 2014. ALPROLIX, a clotting factor IX therapy with prolonged circulation also brought in $10 million in the second quarter of 2014. Biogen also received approval during the quarter from the U.S. Food and Drug Administration (FDA) for ELOCTATE for the control and prevention of bleeding episodes, surgical management and routine prophylaxis in adults and children with hemophilia A.
“This past quarter highlighted significant accomplishments across our business, from the approval of ELOCTATE for hemophilia A, to the continued patient uptake of TECFIDERA in the U.S. and new markets worldwide, to strong clinical results for important emerging MS treatments,”
“We remain focused on additional potential approvals and pivotal read-outs, and continue to look to increase investment in early-stage research to broaden and advance our neurology, immunology and hematology pipelines,” Dr. Scangos added.
NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability from their successful product pipeline, they will need both certified and qualified individuals to promote their diversified therapeutic portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(